Veracyte Prices $51.3M Public Offering

Jul 26, 2018

|

NEW YORK (GenomeWeb) – Veracyte late on Wednesday priced its previously announced public offering of 5 million shares of its common stock at $10.25 per share to raise an anticipated $51.3 million in gross proceeds.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Three for Immunotherapy

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

Testing Less Likely

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

This Week in Genome Research

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Cancer-Fighting Zombies

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.

Featured White Papers

Contract Manufacturing in Biotech: Turning Your Supply Chain Into a Competitive Differentiator

Discovering Neuronal Cell Types

Immuno-Oncology: 3 Strategies for Applying Humanized Models

A Guide to Selecting Your Next Immuno-Oncology Model

Aug

27

Featured Webinar

Case Study: Genetic Testing Lab Sees 25-Fold Scaleup with New Informatics System

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep

17

Featured Webinar

Trends in Clinical NGS QC Management: Expert Insights to Ensure Quality Results for Your Lab

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.

Sep

18

Featured Webinar

Validation and Internal QC of Clinical NGS to Support an Accredited Diagnostic Workflow

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.

Main menu